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Do Negative Expectations Affect Self-Reported Cognitive Functioning and Treatment
Satisfaction After Chemotherapy Treatment for Cancer?
Chairperson: Stuart Hall, Ph.D.
This study investigated the effect of negative expectations on self-reports of cognitive
functioning, treatment satisfaction, and endorsement of a common, negative chemotherapyrelated stereotype in 56 adults who had completed systemic chemotherapy for cancer treatment.
Participants were assigned to either a negative expectation group or a control group. The
negative expectation group had the relationship between chemotherapy and cognitive deficits
overtly brought to their attention, while the control group did not. Both groups completed selfreport measures of cognitive functioning and treatment satisfaction, and then rated their degree
of identification with a chemotherapy-related stereotype. It was hypothesized that the
experimental group would report more negative cognitive symptoms, less treatment satisfaction,
and greater endorsement of the stereotype than the control group. Results revealed no significant
differences between the two groups on these measures. Mean scores for both groups indicated
high ratings of cognitive functioning and treatment satisfaction, however on a different measure,
participants from both groups endorsed a moderate level of cognitive difficulties. Potential
explanations for this inconsistent finding will be discussed. Further investigation may add to
existing knowledge about the influence of negative expectations on self-reported functioning and
may help inform optimal methods of interacting with cancer patients and others with chronic
disorders.
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Do Negative Expectations Affect Self-Reported Cognitive Functioning and Treatment
Satisfaction After Chemotherapy Treatment for Cancer?
Worldwide, there are approximately 14.5 million people alive today who are survivors of
cancer (American Cancer Society, 2014). By 2024, that number is expected to reach nearly 19
million (American Cancer Society, 2014). While rates of cancer diagnosis continue to rise,
cancer mortality rates have declined due to factors such as increased screening, early detection,
and advances in treatment. As ever more people survive a diagnosis of cancer, issues related to
cancer survivorship become increasingly important.
Returning to the activities of daily life after treatment for cancer can be a difficult
process. For example, persisting physical symptoms such as fatigue and pain may impede a
successful transition back to the workplace or to school (Horneber, Fischer, Dimeo, Ruffer, &
Weis, 2012; Pertl, Quigley, & Hevey, 2014). Psychological symptoms such as anxiety and
depression are common experiences both during and after treatment and can negatively impact
the recovery process for cancer survivors (Hinz, Krauss, Hauss, Hockel, Kortmann, Stolzenburg,
& Schwartz, 2010; Linden, Vodermaier, MacKenzie, & Greig, 2012; Mitchell, Chan, Bhatti,
Halton, Grassi, Johansen, & Meader, 2011; Raffa & Tallarida, 2010; Reyes-Gibby, Anderson,
Morrow, Shete, & Hassan, 2012).
Chemotherapy-Related Cognitive Impairment (CRCI)
Individuals undergoing, or who have undergone chemotherapy treatment for cancer,
frequently describe negative changes in their cognitive abilities (Ahles & Saykin, 2007;
Ferguson & Ahles, 2003; Hodgson, Hutchinson, Wilson, & Nettelbeck, 2013; Johnston, 2013;
Porter, 2013; Pullens, De Vries, Van Warmerdam, Van De Wal, & Roukema, 2013; Simo, RifaRos, Rodriguez-Fornells, & Bruna, 2013). Colloquially referred to as “chemo-brain” (Mann,
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1999) or “chemo-fog” (Mitchell & Turton, 2011; Raffa & Tallarida, 2010), chemotherapyrelated cognitive impairment, or CRCI (Argyriou, Assimakopoulos, Iconomou, Giannakopoulou,
& Kalofonos, 2011; Holmes, 2013), consists of a constellation of frequently reported symptoms
that include problems with attention, concentration, and memory (Joly, Rigal, Noal & Giffard,
2011; Matsuda, Takayama, Tashiro, Nakamura, Ohashi, & Shimozuma, 2005; Schagen, van
Dam, Muller, Boogerd, Lindebloom, & Bruning, 1999; Vardy & Tannock, 2007; Wieneke &
Dienst, 1995). A subset of cancer patients treated with chemotherapy (12-68%) demonstrate
impairment on neuropsychological tests (Ahles & Saykin, 2007; Johnston, 2014; Joly, Rigal,
Noal, & Giffard, 2011; Lindner, Phillips, McGabe, Mayes, Wearden, Varese, & Talmi, 2014;
Shilling, Jenkins, & Trapala, 2006). Problems with attention, concentration, and memory may
contribute to a lower quality of life after cancer diagnosis and treatment (Hodgson, Hutchinson,
Wilson, & Nettelbeck, 2013; Meyers, 1999; Mitchell & Turton, 2011; Short, Vasey, & Tunceli,
2005; Simo, Rifa-Ros, Rodriguez-Fornells, & Bruna, 2013). Although cognitive difficulties after
chemotherapy have been shown to diminish over time (Hodgson, Hutchinson, Wilson, &
Nettelbeck, 2013; Hutchinson et al., 2012; Lindner, Phillips, McGabe, Mayes, Wearden, Varese,
& Talmi, 2014), Ahles and Saykin (2002) and Reneman, et al. (2011) demonstrated enduring
cognitive deficits in a sample of cancer survivors more than 10 years after treatment had ended.
History and Etiology of CRCI
It was likely Silberfarb, Philibert, and Levine (1980) who first reported a possible link
between chemotherapy and declines in cognitive functioning. Silberfarb and colleagues
administered cognitive tests (Trail Making Test B, Digit Symbol Coding, Cognitive Capacity
Screening Test) and self-report measures (Self-Rating Depression Scale and Multiple Affect
Adjective Check List) to 50 medical oncology patients. Results revealed cognitive impairment as
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a “common occurrence” in the absence of affective disorders or other psychopathology
(Silberfarb et al., 1980). Based on these findings, Silberfarb and colleagues identified
chemotherapy as the underlying common factor amongst the patients and cautioned that
consulting mental health providers be aware that changes in cognitive and emotional functioning
may be due, in part, to treatment with chemotherapy (1980).
Inquiries regarding chemotherapy-related cognitive impairment (CRCI) have become
increasingly complex and intensely debated since the work of Silberfarb, Philibert, and Levine
(1980). While use of the term “chemo-brain” has become widespread among patients, medical
providers, and researchers, its etiology is not well understood (Ahles & Saykin, 2001; AndersonHanley, Sherman, Riggs, Agocha & Compas, 2003; Jansen, Miaskowski, Dodd, Dowling &
Kramer, 2005; Wieneke & Dienst, 1995). Attempting to isolate the factors that contribute to
CRCI has become a major challenge. Numerous biological and psychological factors likely
interact to produce the phenomenon of CRCI. For example, cognitive impairments in individuals
with cancer often occur alongside fatigue, pain, anxiety, and depression (Horneber, Fischer,
Dimeo, Ruffler & Weis, 2012; Linden, Vodermaier, MacKenzie & Greig, 2012; Pertl, Quigley &
Hevey, 2014; Singer et al., 2013; Spiegel & Giese-Davis, 2003). Consequently, there is
uncertainty regarding whether CRCI should be considered a cause or a consequence of these
negative affective states (Hermelink, 2011; Jacobs, Jacobsen, Booth-Jones, Wagner, & Anasetti,
2007; Tope, Ayles, & Silberfarb, 1993). The fact that not all patients experience cognitive
deficits suggests that some patients may be more susceptible to CRCI than others. This
susceptibility could be associated with many factors such as premorbid impairments,
comorbidities, genetic predisposition, cancer type, and treatment protocol (Argyriou,
Assimakopoulos, Iconomou, Giannakopoulou, & Kalofonos, 2011; Wefel, Saleeba, Buzdar, &
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Meyers, 2010; Zucca, Boyes, Linden, & Girgis, 2012). The ability to identify the subset of
patients most susceptible to CRCI would permit comprehensive treatment strategies before
chemotherapy begins, such as establishing an individual’s baseline level of cognitive
functioning, psycho-education around CRCI, psychotherapy for coping with emotional distress,
and the addition of supportive pharmacotherapies (Joly, Rigal, Noal & Giffard, 2011; Raffa,
2011).
Measurement of CRCI
A thorough understanding of cognitive impairment after chemotherapy requires that
changes in functioning be detected and measured. Perhaps the most universal and puzzling
finding associated with the measurement of CRCI is the discrepancy that exists between
individuals’ scores on self-report measures of cognitive functioning and their scores on
neuropsychological measures of cognitive functioning (Bender, Sereika, Berga, et al., 2006;
Evenden, 2013; Myers, 2012; Rugo & Ahles, 2003; Schilder et al., 2012; Weis, Poppelreuter, &
Bartsch, 2009). It is common for survivors to self-report a high degree of cognitive impairment
yet demonstrate minimal to moderate impairment on objective measures of cognitive functioning
(Ferguson, McDonald, Saykin, & Ahles, 2007; Hodgson, Hutchinson, Wilson, & Nettelbeck,
2013; Rugo & Ahles, 2003; Schilder et al., 2012). In numerical terms, 83% of individuals treated
with chemotherapy self-report cognitive impairments (Jenkins et al., 2006; Kohli et al., 2006;
O’Schaughnessy, 2003), yet only 12-68% demonstrate impairments on neuropsychological tests
(Ahles & Saykin, 2007; Shilling, Jenkins, & Trapala, 2006). The lack of congruence between
subjective and objective evaluations suggests that these evaluations are measuring either
different facets of one construct, or two separate constructs (Hermelink et al., 2010; Hutchinson,
Hosking, Kichenadasse, Mattiske & Wilson, 2012). The lack of a strong association between
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scores on self-reports (subjective measures) and scores on neuropsychological tests (objective
measures) may have multiple explanations. Methodological issues have been identified as
contributing to the discrepancy between subjective and objective measurements of functioning
(Kaiser, Bledowski, & Dietrich, 2014; Porter, 2013; Pullens, De Vries, Van Warmerdam, Van
De Wal, & Roukema, 2013; Schagen et al., 2002; Schagen, 2007; Seigers & Fardell, 2011).
Methodological Contributors to the Discrepancy in Findings
Comparison Groups
One primary methodological problem faced by CRCI researchers lies in the selection of
an appropriate comparison group to whom survivors’ scores are compared (Hodgson,
Hutchinson, Wilson, & Nettelbeck, 2013; Jansen et al., 2005; Kaiser, Bledowski, & Dietrich,
2014; Pullens, De Vries, Van Warmerdam, Van De Wal, & Roukema, 2013; Schilder et al.,
2012). Group differences may cause patients’ scores on neuropsychological tests to appear
“better” or “worse” depending on whether the scores are compared to those of healthy controls,
cancer patients who received only localized treatment, or to patients’ own baseline levels of
cognitive functioning. The last comparison (comparing patients to their own baseline) is
particularly scarce in the literature, as a limited number of studies have successfully collected
pre-chemotherapy data. Contributing to a lack of baseline data may be the pressure that patients
feel to begin treatment following a life-threatening diagnosis (Hodgson, Hutchinson, Wilson, &
Nettelbeck, 2013; Joly, Rigal, Noal, & Giffard, 2011; Mitchell & Turton, 2011; Stewart,
Bielajew, Collins, Parkinson, & Tomiak, 2006). Neuropsychological findings based on withingroup comparisons have often not reached statistical significance (Jansen, Miaskowski, Dodd,
Dowling, & Kramer, 2005; Lindner, Phillips, McGabe, Mayes, Wearden, Varese, & Talmi,
2014). Some researchers have suggested that the small sample sizes used in this type of
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comparison do not allow for sufficient power to detect an effect if one is there (Hodgson,
Hutchinson, Wilson, & Nettelbeck, 2013; Porter, 2013; Seigers & Fardell, 2011). Other
hypotheses that have been put forth to explain inconclusive findings propose that effects may
vary with treatment type, treatment intensity and duration, and that effects may vary depending
on when (during or after treatment) data are collected (Evenden, 2013; Hodgson, Hutchinson,
Wilson, & Nettelbeck, 2013; Quesnel, 2009; Schilder, Eggens, Seynaeve, et al., 2009; Simo,
Rifa-Ros, Rodriguez-Fornells, & Bruna, 2013). Research indicates that the most striking effects
occur either during, or shortly after treatment, however the duration of impairments is not well
understood and effects have been found many years after treatment has ended (Ahles & Saykin,
2002; Evenden, 2013; Mitchell & Turton, 2011; Monje & Dietrich, 2012; Porter, 2013; de Ruiter
et al., 2011; Simo, Rifa-Ros, Rodriguez-Fornells, & Bruna, 2013; Wigmore, 2013).
Instrument-Related Confounds
A second methodological problem that could contribute to the discrepancy between
scores on self-report and objective measures includes instrument-related confounds (Hodgson,
Hutchinson, Wilson, & Nettelbeck, 2013; Jansen, Miaskowski, Dodd, & Dowling, 2007;
Lindner, Phillips, McGabe, Mayes, Wearden, Varese, & Talmi, 2014; Porter, et al., 2013;
Schilder et al., 2012). One challenging problem when attempting to make comparisons across
studies, regards the classification of neuropsychological tests to particular domains of cognitive
functioning (Hodgson, Hutchinson, Wilson, & Nettelbeck, 2013; Jansen, Miaskowski, Dodd,
Dowling, & Kramer, 2005; Lindner, Phillips, McGabe, Mayes, Wearden, Varese, & Talmi,
2014). Multiple tests can be used to measure a single cognitive domain and researchers differ in
their preference for particular tests for particular domains. Consequently, it can be difficult to
link individual tests with the scores that are provided. Lindner and colleagues (2014) suggest
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guidelines that would facilitate the objective measurement of impairments in future studies.
Examples that are germane to this discussion include the following guidelines: the use of shorter
neuropsychological batteries that specifically focus on certain cognitive functions; when using
neuropsychological tests, strive to use very similar versions of the same cognitive tests between
research groups and report the same scores; and consistently group test scores into cognitive
functions, as the high number of neuropsychological tests makes it difficult to understand
whether two different results refer to the same function (Lindner, Phillips, McGabe, Mayes,
Wearden, Varese, & Talmi, 2014).
A second instrument-related problem includes the use of measures that are insensitive to
mild to moderate impairments (Jacobs, Jacobsen, Booth-Jones, Wagner, & Anasetti, 2007;
Mitchell & Turton, 2011; Porter, 2013). Neuropsychological measures that are used to capture
more profound deficits in cognitive functioning, such as The Mini Mental State Examination, are
of little use in the detection of mild to moderate cognitive changes (Evens & Eschiti, 2009;
Lindner, Phillips, McGabe, Mayes, Wearden, Varese, & Talmi, 20142014; Meyers, Geara,
Wong, & Morrison, 2000; Mitchell and Turton, 2011). As research continues, it will become
imperative to establish a consistent neuropsychological battery that is both brief, sensitive, and as
resistant to practice effects as possible (Hodgson, Hutchinson, Wilson, & Nettelbeck, 2013;
Jacobs, Jacobsen, Booth-Jones, Wagner, & Anasetti, 2007; Lindner, Phillips, McGabe, Mayes,
Wearden, Varese, & Talmi, 2014; Vardy, Wefel, Ahles, Tannock, & Schagen, 2008).
Numerous factors limit the detection and objective measurement of impairments in
cognitive functioning after chemotherapy. The two broad methodological problems discussed
above (appropriate comparison groups and instrument-related confounds) should also be
considered within the larger context of CRCI research in general. The systematic study of the
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effect of chemotherapy on cognitive functioning is in its early stages. There are only a handful of
meta-analyses that offer effect sizes for the effect of chemotherapy on specific domains of
cognitive functioning (Falleti, Sanfilippo, Maruff, Weih, and Phillips, 2005; Hodgson,
Hutchinson, Wilson, & Nettelbeck, 2013; Jansen, Miaskowski, Dodd, Dowling, & Kramer,
2005; Stewert, Bielajew, Collins, Parkinson, & Tomiak, 2006) and these few meta-analyses base
their effect sizes on scores on objective neuropsychological tests only. Direct comparisons
between studies are often impractical because of inconsistencies in the literature about what to
measure and how to measure it (Anderson-Hanley, Sherman, Riggs, Agocha, & Compas, 2003;
Jansen, Miaskowski, Dodd, Dowling, & Kramer, 2005). Despite these challenging factors,
conclusions based on objective neuropsychological testing have been put forth regarding the
effects of chemotherapy on cognition.
Neuropsychological Measurement of CRCI
Meta-analyses that have summarized the objective, neuropsychological findings of earlier
studies have shown that individuals treated with chemotherapy demonstrate a wide range of
small to moderate cognitive deficits when compared to normal controls. These deficits occur in
the following areas: attention, processing speed, verbal and visual memory, long-term and
working memory, visuospatial skills, executive functioning, and motor functioning (AndersonHanley, Sherman, Riggs, Agocha, & Compas, 2003; Falleti, Sanfilippo, Maruff, Weih, &
Phillips, 2005; Jansen, Miaskowski, Dodd, Dowling, & Kramer, 2005; Stewart, Bielajew,
Collins, Parkinson, & Tomiak, 2006).
Lindner, Phillips, McGabe, Mayes, Wearden, Varese, & Talmi (2014) built on the
investigation of the objective measurement of cognitive functioning after chemotherapy by
conducting a meta-analysis of the results from 44 studies published between 1980 and January
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2011. Studies were subdivided into cross-sectional and longitudinal designs. Results from studies
using cross-sectional designs showed impairments on immediate free recall, delayed memory,
verbal memory, delayed recognition memory, selective attention, and attention capacity, with
small effect sizes at or slightly above d = 0.20. Results from studies using longitudinal designs
showed more moderate effect sizes across multiple functions, but that patients performed better
in follow-up evaluations than at baseline (Lindner, Phillips, McGabe, Mayes, Wearden, Varese,
& Talmi, 2014).
Subjective Report versus Objective Measurement
A difference of opinion exists within CRCI literature regarding the etiology of the
discrepancy between scores on self-report versus objective measures. Some research has
attributed the difference in scores on objective versus subjective measures solely to flaws in
methodology or issues in neuropsychological testing (Hermelink et al., 2010, Jansen,
Miaskowski, Dodd, Dowling & Kramer, 2005; Shilling & Jenkins, 2007). For example, it has
been proposed that if neuropsychological tests were improved, larger effects would be observed.
Improvements in objective measures likely would increase the size of the observed effects, but
may not fully explain the discrepancy between subjective objective measures. Alternatively,
other research has considered scores on subjective measures to be the most accurate indicators of
cognitive functioning (Hermelink et al., 2010). The utility of this perspective is limited by
research that has demonstrated the effect of secondary factors (e.g., negative affective states like
depression) on self-reports of functioning (Joly, Rigal, Noal, & Giffard, 2011; O’Connor et al.,
2012; Zucca, Boyes, Linden, & Girgis, 2012). In addition to cognitive impairment, self-reported
negative symptoms may reflect factors such as the experience of emotional distress (depression,
sadness, anxiety, fear, worry, anger, panic) involved in coping with a life-threatening disease
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(Andrykowski, Lykins, & Floyd, 2008; Argyriou, Assimakopoulos, Iconomou, Giannakopoulou,
& Kalofonos, 2011).
Secondary Factors that Influence the Experience of CRCI
The literature is replete with examples of research that demonstrate the influence of
secondary factors on test performance (Croizet & Claire, 1998; Levy, 1996; Spencer, Steele, &
Quinn, 1999; Steele & Aronson; 1995, & Steele, 1997) and it is widely accepted that physical
and psychological symptoms affect cognitive functioning (Joly, Rigal, Noal, & Giffard, 2011;
O’Connor et al., 2012; Zucca, Boyes, Linden, & Girgis, 2012). For cancer survivors, the
discrepancy between scores on objective versus subjective measures of cognitive functioning
may be due, in part, to factors such as negative affective states. Undoubtedly, it is common for
individuals to experience symptoms of depression and anxiety immediately following a
diagnosis of cancer (Anderson, Golden-Kreutz, Emery, & Thiel, 2009; Andrykowski, Lykins, &
Floyd, 2008; Hill et al., 2010; Mehnert et al., 2012; Spiegel & Giese-Davis, 2003), and numerous
studies have reported an association between depression, anxiety, and cognitive complaints
(Cimpich, Ronis, & Trask, 2005; Cull et al., 1996; Schagen, Boogerd, & Muller, 2008; Schagen,
van Dam, Muller, Boogerd, Lindeboom, & Bruning,1999; Schilling & Jenkins, 2007, Velde,
Linn, Nortier, Schilder, Seynaeve, Gundy, …& van Dam, 2012). Increased symptoms of
depression and anxiety may serve to intensify the perception of negative cognitive symptoms
after chemotherapy.
Stereotype Threat
Another possible explanation for the discrepancy between scores on subjective and
objective measures of functioning may be related to the idea of stereotype threat (Steele &
Aronson, 1995). Steele and Aronson (1995) describe stereotype threat, “… as a social-
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psychological predicament that can arise from widely known stereotypes about one’s group,”
(1995, p. 797). Stereotype threat occurs when a person experiences the threat of being judged or
treated stereotypically, or fears fulfilling a stereotype (Steele & Aronson, 1995). Research in the
field of social psychology has shown that the activation of a stereotype can greatly impact the
way individuals think and behave (Hamilton & Sherman, 1994; Steele & Aronson, 1995; Steele,
1997). Stereotypes, or fixed schemas, can be described as mental representations of prior
knowledge and experiences (Kunda, 1999; Schagen, Das, & van Dam, 2009). These schemas can
be made accessible through the process of priming, whereby contextual information is provided
to the individual that results in the activation of the mental representation or stereotype (Steele,
1997). Both positive and negative stereotypes may be activated. For example, Margaret Shih and
colleagues (2002) showed that activation of a positive stereotype “boosted” performance for
Asian students on a math test when this positive stereotype was subtly called to their attention
(Shih, M., Ambady, N., Richeson, J. A., Fujita, K., & Gray, H. M., 2002). Conversely, Kaye &
Pennington (2016) examined the performance of females and males on a computer gaming task
where females were told (prior to the task) that they have been shown to underperform males on
various gaming tasks. Results showed that females performed more poorly than males (negative
stereotype activation) on the task (Kaye, L. K., & Pennington, C. R., 2016). The process of
activating a negative stereotype is referred to as stereotype threat (Steele & Aronson, 1995).
One of the first published examples of Stereotype Threat involved a series of experiments
that focused on Black and White students and intellectual test performance (Steele & Aronson,
1995). The experimental group consisted of both Black and White students. This group was told
that their performance on a test (Graduate Record Exam (GRE) items) would be diagnostic of
academic ability. This statement served to make negative racial stereotypes about the intellectual
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ability of Blacks salient to Black participants. The control group also consisted of Black and
White students. This group was not told that the test measured academic ability before taking the
test. Results showed that Black students performed more poorly than White students under the
threat condition (being told the test measured academic ability), but matched White students
under the neutral condition (not being told the test measured academic ability). This study clearly
demonstrated the power of Stereotype Threat; negative expectations affected African Americans’
performance and served to lower their scores. The influence of negative expectations on test
performance has been demonstrated extensively in the literature (Croizet & Claire, 1998; Levy,
1996; Spencer, Steele, & Quinn, 1999; Suhr & Gunstad, 2002; Suhr & Gunstad, 2005; Steele &
Aronson; 1995, & Steele, 1997).
Diagnosis Threat
In 2002, Suhr and Gunstad applied the concept of negative expectancies to the study of
traumatic brain injury (TBI). Suhr and Gunstad recruited participants with a previous diagnosis
of TBI. The participants, who all had a prior history of TBI, were assigned to either the
experimental group or the control group. Participants in the experimental group (N = 17) were
told that individuals with a history of prior TBI would likely perform poorly on measures of
cognitive functioning due to their prior TBI, whereas participants in the control group (N = 19)
were simply told to put forth their best effort. Both groups completed measures of functioning
(memory, intellect, attention, and psychomotor speed) and the results were compared. The
experimental group did, in fact, perform more poorly than the control group on objective
measures of cognitive functioning. Because decrements in performance were observed following
activation of negative expectations related to a prior diagnosis, Suhr and Gunstad named this
process diagnosis threat (2002).
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In 2005, Suhr and Gunstad continued their investigation of the effect of diagnosis threat
on cognitive performance in a sample of college students with a history of mild TBI. Suhr and
Gunstad wanted to know whether anxiety, effort, and depression in fact drive the experience of
diagnosis threat. Participants were assigned to either a diagnosis threat condition (n = 28) or a
control condition (n = 25). Participants completed measures of anxiety (State Trait Anxiety
Inventory and a Likert scale that provided self-reported pressure during testing), measures of
effort (Word Memory Test and a Likert scale that provided self-reported effort during testing),
and a measure of depression (Beck Depression Inventory, Second Edition). Neuropsychological
tests measured memory, psychomotor speed, attention, and executive functioning. Results were
consistent with prior findings and demonstrated that those in the diagnosis threat condition
performed worse than those in the control condition on neuropsychological tests. However,
contrary to predictions, no differences arose between the groups on anxiety, effort, or depression.
These findings suggest that anxiety, effort, and depression did not account for the differences
between the groups on objective measures of functioning. Questions remain regarding the causes
of diagnosis threat. Wheeler and Petty (2001) contend that activation of schemas related to a
stereotype explains the experience of diagnosis threat more than affect or motivational changes
due to that threat.
Trontel, Hall, Ashendorf, and O’Conner (2013) further explored diagnosis threat by
examining its impact on academic self-efficacy and neuropsychological test performance in
individuals with mild traumatic brain injury. All participants had prior diagnoses of mild TBI
and were randomly assigned to either a diagnosis threat group or a control group. Individuals in
the diagnosis threat group were told that they were selected for participation based on their prior
diagnosis of TBI, while those in the control group were told to perform to the best of their ability
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(Trontel, Hall, Ashendorf, & O’Connor, 2013). Results revealed that the groups performed
differently on just one objective neuropsychological measure. However, the participants in the
diagnosis threat group self-reported significantly lower academic self-efficacy than participants
in the control group. This finding suggests that diagnosis threat may have a larger impact on selfreport than on objective cognitive performance.
Other Examples of Negative Expectations
In 2009, Schagen, Das, and van Dam examined CRCI using a diagnosis threat type of
methodology. The researchers conducted interviews with patients at the Netherlands Cancer
Institute. Patients were interviewed about the occurrence of fatigue, insomnia, and memory and
concentration problems. Patients were asked to rate the extent of each complaint using a 5-point
Likert type scale, where 1 indicated ‘not at all,’ and 5 indicated ‘extremely.’ For half of the
interviews, participants were told that ‘some patients treated with cytotoxic agents
(chemotherapy) experience cognitive problems,’ and that the goal of the study was to ‘obtain
more insight into the relationship between chemotherapy and cognitive problems. The other half
of patients (the control group) received a neutral introduction with no mention of the association
between chemotherapy and cognitive impairments. After the interviews, all patients were asked
whether they were familiar with, or had knowledge of, the CRCI stereotype.
Results of this experiment were somewhat surprising. First, physical symptoms such as
fatigue, insomnia, and limited endurance were the most frequently reported symptoms. Second,
individuals with prior knowledge about the CRCI stereotype (those who had heard of the CRCI
stereotype unrelated to the experiment) reported more complaints than individuals without prior
knowledge of the CRCI stereotype regardless of the type of complaint (cognitive v. physical).
And third, activating the CRCI stereotype had an overall greater effect on the cognitive
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complaints made by individuals with no prior knowledge of the CRCI stereotype than those with
prior knowledge of the CRCI stereotype (Schagen, Das, & van Dam, 2009). This study
demonstrated that activating the CRCI schema increased all individuals’ reports of cognitive
complaints, and that these complaints increased most significantly for individuals with no prior
knowledge of the CRCI schema. This result suggests that patients with little to no knowledge
about CRCI may be the most susceptible to the experience of CRCI. This finding is especially
poignant in light of the fact that patients often report having received little pre-treatment
education about the effects of chemotherapy on cognition (Evens & Eschiti, 2009; Mitchell &
Turton, 2011; Myers, 2012; Porter, 2013, Schagen, Das, & van Dam, 2009).
Negative expectations related to treatment with chemotherapy may operate by a
mechanism like that involved in negative expectations related to a prior diagnosis. Negative
expectations related to treatment with chemotherapy may influence the degree and frequency
with which cancer survivors report symptoms of cognitive decline. It may also be true that
activation of negative expectations related to treatment produces effects that are not limited to
cognitive functioning. Understanding the full impact of negative expectations on different
aspects of survivors’ health may help inform pretreatment psycho-education strategies and periand post- treatment coping and remediation strategies. The current work sought to expand the
investigation of negative expectations in cancer survivors by examining not only its impact on
cognitive functioning in individuals who have received treatment with chemotherapy, but also its
impact on treatment satisfaction, and endorsement of a chemotherapy-related stereotype both
during and after treatment. It was hypothesized that individuals in the negative expectations
group would report more negative cognitive symptoms, less treatment satisfaction, and greater
endorsement of a chemotherapy-related stereotype than participants in the control group.
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Hypotheses Related to Cognitive Functioning (Primary Hypotheses)
1) Participants in the negative expectations group will report significantly more
perceived cognitive impairments than participants in the control group, as measured
by the mean scores of the two groups on the ‘Perceived Cognitive Impairments’
subscale of the FACT-Cog (Version 3).
2) Participants in the negative expectations group will report significantly more negative
comments from others about their cognitive functioning than participants in the
control group, as measured by the mean scores of the two groups on the ‘Comments
From Others’ subscale of the FACT-Cog (Version 3).
3) Participants in the negative expectations groups will report significantly fewer
cognitive abilities than participants in the control group, as measured by the mean
scores of the two groups on the ‘Cognitive Abilities’ subscale of the FACT-Cog
(Version 3).
4) Participants in the negative expectations group will report that perceived cognitive
impairments have a significantly greater negative impact on quality of life than
participants in the control group as measured by the mean scores of the two groups on
the ‘Impact on Quality of Life’ subscale of the FACT-Cog (Version 3).
Hypotheses Related to Treatment Satisfaction
5) Participants in the negative expectations group will report significantly lower scores
related to satisfaction with physician communication than the control group, as
measured by the mean scores of the two groups on the ‘Physician Communication’
subscale of the FACIT-TS-PS (Version 4).
6) Participants in the negative expectations group will report significantly lower scores
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related to satisfaction with treatment staff communication than the control group, as
measured by the mean scores of the two groups on the ‘Treatment Staff
Communication’ subscale of the FACIT-TS-PS (Version 4).
7) Participants in the negative expectations group will report significantly lower scores
related to overall treatment satisfaction than will the control group as measured by the
mean total scores of the groups on the FACIT-TS-PS (Version 4).
Hypotheses related to Endorsement of a Chemotherapy-Related Stereotype
8) Participants in the negative expectations group will report greater endorsement of a
stereotype during treatment than participants in the control group, as measured by the
mean scores on the Perceived Impairments Scale during treatment.
9) Participants in the negative expectations group will report greater endorsement of a
stereotype after treatment than will participants in the control group, as measured by
mean scores on the Perceived Impairments Scale after treatment.
Method
Participants
A total sample of 56 male and female participants between the ages of 25 years and 93
years (M = 63.7 years, SD = 15.38) was collected over a three-month period at an outpatient
cancer treatment center in the northwestern United States. Participants received a gift card valued
at $20.00 for participation in the study. All participants were 18 years of age or older, had
completed chemotherapy for the treatment of cancer prior to study participation, were not
between courses of treatment, and were not entering palliative care.
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Instruments
Demographic Questionnaire (see Appendix A)
The demographic questionnaire includes questions about the participant’s age, education,
psychological history (such as prior diagnoses and treatment), medical history (such as prior
neurological conditions or history of traumatic brain injury), and oncology history (such as type
of cancer, treatment duration, and time since last treatment).
Instructions for Negative Expectations Group (see Appendix B)
Participants in the negative expectations group will be told in writing that they were
chosen to participate due to their prior diagnosis of cancer and treatment with chemotherapy. The
instructions will draw their attention to the fact that some oncology patients report experiencing
problems with thinking and memory after chemotherapy. The instructions will then ask
participants to complete the self-report questionnaires as thoroughly and accurately as possible.
Participants in the negative expectations group will be asked to sign a form indicating that they
read and understood the instructions.
Instructions for Control Group (see Appendix C)
Instructions for the control group will not overtly draw participants’ attention to the
relationship between chemotherapy and cognitive impairments. Instructions will simply ask
participants in the control group to complete all questionnaires as thoroughly and accurately as
possible. Control group participants will be asked to sign a form indicating that they read and
understood the instructions.
Self-Report Measures (see Appendices D and E)
The self-report measures that will be used in the current study are a part of the Functional
Assessment of Chronic Illness Therapy (FACIT) Measurement System developed by David
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Cella, Ph.D. and colleagues. The FACIT Measurement System includes a range of health-related,
quality of life questionnaires for individuals with chronic illnesses. The questionnaires have been
validated and are targeted for the management of chronic illness. A subset of FACIT
questionnaires, The Functional Assessment of Cancer Therapy (FACT) instruments, were
specifically designed to assess cancer therapy and have been validated for use with individuals
who are currently receiving treatment and with individuals who have finished receiving
treatment (Cella et al., 1993; Webster, Cella, & Yost, 2003; Webster, Odom, Peterman, Lent, &
Cella, 1999, Yellen, Cella, Webster, Blendowski, & Kaplan, 1997).
The FACT-Cognitive Function (Version 3) is a self-report measure consisting of four
subscales: ‘Perceived Cognitive Impairments’ (PCI) with 20 items, ‘Impact On Quality Of Life’
(IQOL) with 4 items, ‘Comments From Others’ (CFO) with 4 items, and ‘Perceived Cognitive
Abilities’ (PCA) with 9 items. Participants were asked to indicate the frequency with which they
experienced symptoms on each of the four scales over the course of the previous week. Response
options included: ‘Never’, ‘About once a week’, ‘Two to three times a week’, ‘Nearly every
day’, and ‘Several times a day’. Negatively worded items on the FACT-Cog are reverse-scored
such that higher scores on this measure indicate better functioning. Per FACT-Cog, V3 scoring
guidelines, adding subscale scores to obtain total scores is not applicable. Internal consistency
reliability coefficients for PCI, IQOL, CFO, and PCA scales were r = .94, r = .67, r = .90, and r
= .92, respectively. Test-retest reliability coefficients for the PCI, IQOL, CFO, and PCA scales
were r = .82, r = .82, r = .79, and r = .86, respectively. Wagner et al. (2008) found good to
excellent convergent validity (>.70) with the Cognitive Difficulties Scale (CDS), another
frequently used self-report measure of cognitive functioning.

19

The FACIT-TS-PS (Version 4) is a self-report measure of patient treatment satisfaction.
The FACIT-TS-PS (Version 4) includes six scales: ‘Physician Communication,’ ‘Treatment
Staff Communication,’ ‘Technical Competence,’ ‘Nurse Communication,’ ‘Confidence and
Trust,’ and ‘Overall’ treatment satisfaction. Two subscales ‘Physician Communication’ and
‘Treatment Staff Communication’ along with the FACIT-TS-PS Total Score were selected for
analyses. Participants were asked to indicate the quality of the health care services that they
received over the course of their medical care. Response options included: ‘No, not at all,’ ‘Yes,
but not as much as I wanted,’ ‘Yes, almost as much as I wanted,’ and ‘Yes, and as much as I
wanted.’ Negatively worded items on the FACIT-TS-PS, V4 are reverse-scored such that higher
scores on this measure indicate greater treatment satisfaction. Reliability and validity data are
not available for this measure.
Perceived Impairments Scale (see Appendix F)
This scale consisted of two items and was used to assess the degree to which participants
endorsed a chemotherapy-related stereotype during and after treatment. Specifically, participants
rated how accurately a description of negative cognitive symptoms (based on a common
chemotherapy-related stereotype) represented their experience 1) during treatment, and 2) after
treatment. A seven-point Likert scale was used for these two items, where a rating of 0 indicated
‘not accurately at all’ and a rating of 7 indicated ‘perfectly accurately.’
Debriefing Statement (see Appendix G)
A debriefing statement was provided to participants at the end of the study. This form
included information about the purposes of the study and provided contact information for the
researcher if the participant had questions or concerns regarding participation.
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Design and Procedures
Overview
Participants were recruited via flyers provided by physicians during patients’ regularly
scheduled maintenance appointments. Participants were randomly assigned to either an
experimental group or a control group and completed all questionnaires on-site in a quiet
location. Participation took approximately 20 minutes and was followed by debriefing and
receipt of gift card.
Procedure
At the study appointment, participants were escorted to a quiet location on-site where
they completed the Informed Consent Form and the Demographic Questionnaire. Each
participant was then given an envelope with a letter inside that contained study instructions that
also served to assign participants to either an experimental or control group. Participants in the
experimental group were informed by their letter that they were selected for participation due to
their prior cancer diagnosis and treatment with chemotherapy. Participants in the experimental
group also had the relationship between chemotherapy and cognitive impairment brought to their
attention by reading a short paragraph describing CRCI (see Appendix B). These statements
were intended to activate treatment threat in the experimental group prior to completion of the
self-report measures. Participants in the control group were simply instructed to complete the
self-report measures as thoroughly and accurately as possible (see Appendix C). The examiner
exited the room while the participants read the instructions, thereby ensuring that the examiner
was unaware of group assignment at the time of participation. After reading the instructions,
participants were required to sign them, place them back into the envelope, and seal the
envelope. The examiner then re-entered the room and administered the following self-report
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measures: the FACT-Cognitive, Version 3 (FACT-Cog, V3) the FACIT-Treatment SatisfactionPatient Satisfaction, Version 4(FACIT-TS-PS, V4) and the Perceived Impairments Scale. The
session concluded with a debriefing statement (see Appendix G) and distribution of a gift card
valued at $20.00.
Results
Participant Demographics
Gender, Age, and Education
Of the 56 total participants, 26 participants (46.4%) were women and 30 participants
(53.6%) were men. A chi-square goodness-of-fit test indicated no significant difference in the
proportion of males and females identified in the current sample compared with a sample
composed of 50% males and 50% females, X2 (1, n = 56) = .29, p = .593. Results of the chisquare goodness-of-fit test are shown below in Tables 1A and 1B.
Table 1A. Chi-Square Gender Frequencies
Gender

Observed n

Expected n

Residual

Male

30

28.0

2.0

Female

26

28.0

-2.0

Total

56

-

-

Table 1B. Chi-Square Test Statistics
Statistic

Participant Gender

Chi-Square

.286

Degrees of freedom
Asymptotic Significance

1
.593

The mean age of participants in the experimental group was 64.14 years (SD = 17.90,
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min = 26, max = 93). The mean age of participants in the control group was 63.25 years (SD =
12.69, min = 25, max = 87). The mean years of education for participants in the experimental
group was 13.93 (SD = 2.80). The mean years of education for participants in the control group
was 13.57 (SD = 2.20). Descriptive statistics for age and education of each group are reported
below in Table 2.
Table 2. Descriptive Statistics for Age and Education
Variable
Age

Education

Group

n

M(SD)

Median

Min

Max

Skewness

Experimental

28

64.14(17.90)

66

26

93

-0.46

Control

28

63.25(12.69)

64.5

25

87

-0.94

Experimental

28

13.93(2.80)

12

8

20

0.33

Control

28

13.57(2.20)

12

12

18

0.82

Cancer Types
A variety of cancer types were reported by participants. The top three most frequently
occurring cancer types in the sample were (in descending order): lymphoma (23.2%), breast and
leukemia (14.3%), followed by individuals with two or more cancer types (10.7%). A frequency
distribution of sample cancer types is reported below in Graph 1.
Graph 1. Frequency Distribution of Sample Cancer Types
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Treatment Duration and Time Since Last Treatment
The mean length of treatment for the experimental group was 9.68 months for the (SD =
7.85, min = 2, Max = 36). The mean length of treatment for the control group was 7.73 months
(SD = 4.01, min = 2, Max = 18). The mean time since last treatment for the experimental group
was 36.39 months (SD = 25.83, min = less than 1, max = 113). The mean time since last
treatment for the control group was 27.39 months (SD = 28.62, min = less than 1, max = 130).
Descriptive statistics for ‘treatment duration’ and ‘time since last treatment’ are reported below
in Table 3.
Table 3. Descriptive Statistics for Treatment Duration and Time Since Last Treatment
Variable

Group

n

M(SD)

Median

Min

Max

Skewness

Treatment
Duration
(months)

Experimental

28

9.68(7.85)

6.5

2

36

1.87

Control

28

7.73(4.01)

6.0

2

18

0.65

Time Since
Last Treatment
(months)

Experimental

28

26.39(25.83)

18.5

1

113

1.45

Control

28

27.39(28.62)

16.0

<1

130

1.89

Mental Health Concerns
Of the 56 participants, 12 participants (21.43%) reported mental health concerns and 44
participants (78.57%) reported no mental health concerns at the time of participation. Of the 12
participants who endorsed current mental health concerns, five reported anxiety, four reported
depression, and three reported a combination of anxiety and depression. Of the 12 participants
who endorsed current mental health concerns, six were receiving treatment for mental health
issues at the time of participation and six were not receiving treatment for mental health issues at
the time of participation. Of those six participants receiving treatment at the time of participation,
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four reported pharmacotherapy only and two reported psychotherapy only. These data, and their
relative representation in each group (experimental or control) are shown below in Table 4.
Table 4. Mental Health by Group

Variable
Mental Health Concerns at Time of
Participation
Total n = 12
(21.43% of total sample of n = 56)
Anxiety
n=5
Depression
n=4
Anxiety and Depression
n=3
Receiving Treatment
n=6
No Treatment
n=6
Pharmacotherapy only
n=4
Psychotherapy only
n=2

n

Percent of Total
Sample (n = 56)

Experimental

4

7.14

Control

8

14.29

Experimental

3

5.36

Control

2

3.57

Experimental

1

1.79

Control

3

5.36

Experimental

0

0

Control

3

5.36

Experimental

3

5.36

Control

3

5.36

Experimental

1

1.79

Control

5

8.93

Experimental

1

1.79

Control

3

5.36

Experimental

1

1.79

Control

1

1.79

Group

I. The Effect of Group on Self-Reported Cognitive Functioning as measured by the FACTCognitive, Version 3 (FACT-Cog, V3)
The FACT-Cog consists of 4 independent subscales: 1) ‘Perceived Cognitive
Impairments’, 2) ‘Comments From Others’, 3) ‘Perceived Cognitive Abilities’, and 4) ‘Impact
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On Quality Of Life.’ Four comparisons were planned, thus a Bonferroni adjustment to alpha was
obtained (.05/4 = .0125 = .013) to minimize the risk of Type I error.
1. ‘Perceived Cognitive Impairments’
An independent samples t-test revealed no significant difference in the mean scores on
the Perceived Cognitive Impairments subscale of the FACT-Cog, V3 for the experimental (M =
51.04, SD = 19.20) and control (M = 50.32, SD = 14.76) groups; t(54) = 0.16, p = .44,
d = .04. In other words, those in the experimental group did not report significantly more
problems with cognitive functioning than the control group. The results, along with the means
and standard deviations for the two groups, are reported below in Table 5.
2. ‘Comments from Others’
An independent samples t-test revealed no significant difference in the mean scores for
the experimental (M = 14.68, SD = 2.83) control groups (M = 14.26, SD = 3.01) on the
Comments From Others subscale of the FACT-Cog, V3, t(53) = .53, p = .30, d = .15. This result
indicated that those in the experimental group did not report significantly more comments from
others about their cognitive functioning than the control group. The results, along with the means
and standard deviations for the two groups, are reported below in Table 5.
3. ‘Perceived Cognitive Abilities’
An independent samples t-test revealed no significant difference in the mean scores for
the experimental (M = 19.19, SD = 7.37) and control groups (M = 19.19, SD = 5.31) on the
Perceived Cognitive Abilities subscale of the FACT-Cog, V3, t(51) = -.004, p = .50,
d = .001. This finding demonstrated that those in the experimental group did not report
significantly fewer cognitive abilities than the control group. The results, along with the means
and standard deviations for the two groups, are reported below in Table 5.
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4. ‘Impact on Quality of Life’
An independent samples t-test was revealed no significant difference in the mean scores
for the experimental (M = 11.93, SD = 4.72) and control groups (M = 11.50, SD = 5.22) on the
Impact on Quality of Life subscale of the FACT-Cog, V3, t(51) = .31, p = .39, d = .09. This
result revealed those in the experimental group did not report a significantly greater negative
impact on quality of life than the control group. The results, along with the means and standard
deviations for the two groups, are reported below in Table 5.
Table 5. FACT-Cog, V3 Subscale Scores by Group
FACT-Cog, V3
Subscales*
Perceived Cognitive
Impairments

Comments From
Others
Perceived Cognitive
Abilities
Impact On Quality
Of Life

Group

n

M(SD)

t

p

d

Experimental
Control

28
28

51.04 (19.20)
50.32 (14.76)

.16
-

.44
-

.04
-

Experimental

28

14.68 (2.83)

.53

.30

.15

Control

27

14.26 (3.01)

-

-

-

Experimental
Control

27
26

19.19 (7.37)
19.19 (5.31)

-.004
-

.50
-

.001
-

Experimental
Control

27
26

11.93 (4.72)
11.50 (5.22)

.312
-

.39
-

.09
-

* For all subscales, higher scores indicate better functioning.
Alpha = .05/4 = 0.013 = 98.7% Confidence Interval

Further examination of mean scores on the FACT-Cog, V3 revealed an unexpected
finding; both groups perceived themselves to have strong cognitive functioning across all four
subscales. Recall that higher scores indicate better functioning on each subscale of this measure.
Participants’ mean scores on each subscale of the FACT-Cog, V3 represent a large portion of the
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total possible score on each subscale. For example, the mean scores for the experimental and
control groups on the ‘Perceived Cognitive Impairments’ subscale were M = 51 and M = 50,
respectively. The highest possible score on this subscale representing the highest possible level
of functioning is 72. Therefore, the mean scores for the experimental group (M = 51) and the
control group (M = 50) represent 71% and 70% of the highest possible score on this subscale.
This pattern of strong ratings continued across the other three subscales of the FACT-Cog, V3.
Mean scores and relative percentages for each group on each subscale of the FACT-Cog, V3, as
well as maximum scores possible per subscale are reported below, in Graph 2.
Graph 2. Mean Scores on Functional Assessment of Cancer Therapy-Cognitive, Version 3
(FACT-Cog, V3) Subscales by Group
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II. The Effect of Group on Degree of Identification with a Chemotherapy-Related
Stereotype During and After Treatment
The Perceived Impairments Scale asked participants to rate their degree of identification
with a chemotherapy-related stereotype over two time periods: 1) ‘Perceived Impairments
During Treatment’ and 2) ‘Perceived Impairments After Treatment’. Two comparisons were
planned, thus a Bonferroni adjustment to alpha was obtained (.05/2 = .0250 = .025) to minimize
the risk of Type I error.
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1. ‘Perceived Impairments During Treatment’
An independent samples t-test revealed no significant difference in the mean scores for
the experimental (M = 3.96, SD = 1.99) and control groups (M = 4.81, SD = 1.73) on the item
that asked participants to rate their endorsement of negative cognitive symptoms during
treatment on the Perceived Impairments Scale, t(53) = -1.69, p = .05, d = .45. The results, along
with the means and standard deviations for the two groups, are reported below in Table 7.
2. ‘Perceived Impairments After Treatment’
An independent samples t-test revealed no significant difference in the mean scores for
the experimental (M = 3.54, SD = 2.12) and control groups (M = 3.89, SD = 1.99) on the item
that asked participants to rate their endorsement of a stereotype after treatment on the Perceived
Impairments Scale, t(53) = -.64, p = .26, d = .17. The results, along with the means and standard
deviations for the two groups, are reported below in Table 7.
Table 7. Perceived Impairments Scale Scores by Group
*Perceived
Impairments Scale
Items
Degree of perceived
impairments during
treatment

Degree of perceived
impairments after
treatment

Group

n

M (SD)

t

p

d

Experimental

28

3.96 (1.99)

-1.69

.05

.45

Control

27

4.81 (1.73)

-

-

-

Experimental

28

3.54 (2.12)

-.64

.26

.17

Control

27

3.89 (1.99)

-

-

-

*For both items, higher scores indicate stronger identification with the CRCI stereotype.
Alpha = .05/2 = 0.0250 = 0.025 = 97.50% Confidence Interval

Additional examination of the mean scores on both items of the Perceived Impairments
Scale offered a second unexpected finding. Both groups endorsed a fair amount of identification
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with the stereotype of decreased cognitive functioning both during and after chemotherapy. This
finding contrasts with patients’ high levels of self-reported cognitive functioning on the FACTCog. Mean scores for the experimental and control groups on item 1: ‘Degree of Perceived
Impairments During Treatment’ were M = 5 and M = 4, respectively. The highest possible score
on this item is 7 (indicating strong identification with the stereotype). Thus, the mean scores for
the experimental group (M = 5) and the control group (M = 4) represent 71% and 57% of the
total possible score on this item. A similar pattern appeared for item 2: ‘Degree of Perceived
Impairment After Treatment. It is worth noting that scores did not decrease from Item 1 to Item 2
for the experimental group, while scores did decrease for the control group. Mean scores and
relative percentages for each group on both items of the Perceived Impairments Scale, as well as
maximum scores possible per item are reported below, in Graph 4.
Graph 4. Mean Scores on Both Items of the Perceived Impairments Scale
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III. The Effect of Group on Self-Reported Treatment Satisfaction as measured by the
FACIT Treatment Satisfaction-Patient Satisfaction, Version 4 (FACIT-TS-PS, V4)
The FACIT-TS-PS, V4 consists of five subscales plus a total score, however only 3
subscales 1) ‘Physician Communication’, 2) ‘Treatment Staff Communication’, and 3) ‘Total
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Score’ were selected for analyses. Three comparisons were planned, thus a Bonferroni
adjustment to alpha was obtained (.05/3 = .0166 = .017) to minimize the risk of Type I error.
1. ‘Physician Communication’
An independent samples t-test revealed no significant difference in the mean scores for
the experimental (M = 33.27, SD = 5.84) and control groups (M = 33.61, SD = 3.45) on the
Physician Communication Subscale of the FACIT-TS-PS, V4, t(54) = -.27, p = .40, d = .07. In
other words, the experimental group did not report significantly less satisfaction with physician
communication than the control group. The results, along with the means and standard deviations
for the two groups, are reported below in Table 6.
2. ‘Treatment Staff Communication’
An independent samples t-test revealed no significant difference in the mean scores for
the experimental (M = 9.71, SD = 3.33) and control groups (M = 9.78, SD = 2.79) on the
Physician Communication Subscale of the FACIT-TS-PS, V4, t(53) = -.08, p = .47, d = .02. This
result indicated that the experimental group did not report significantly less satisfaction with
treatment staff communication than the control group. The results, along with the means and
standard deviations for the two groups, are reported below in Table 6.
3. ‘Total Score’
An independent samples t-test revealed no significant difference in the total scores for the
experimental (M = 59.55, SD = 10.03) and control groups (M = 60.32, SD = 6.95) on the FACITTS-PS, V4, t(54) = -.33, p = .37, d = .09. This finding demonstrated that the experimental group
did not report significantly less overall treatment satisfaction than the control group. The results,
along with the means and standard deviations for the two groups, are reported below in Table 6.
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Table 6. FACIT-TS-PS, V4 Subscale Scores by Group
FACIT-TS-PS,
V4 Subscales*

Group

Physician
Communication

Treatment Staff
Communication

Total Score

n

M(SD)

t

p

d

Experimental

28

33.27 (5.84)

-.27

.40

.07

Control

28

33.61 (3.45)

-

-

-

Experimental

28

9.71 (3.33)

-.08

.47

.02

Control

27

9.78 (2.79)

-

-

-

Experimental

28

59.55 (10.03)

-.33

.37

.09

Control

28

60.32 (6.95)

-

-

-

* For all subscales, higher scores indicate better functioning.
Alpha = .05/3 = 0.0166 = 0.017 = 98.3% Confidence Interval

Like the high ratings seen on the FACT-Cog, ratings on the FACIT-TS-PS, V4 were also
high, indicating that patients in both groups were highly satisfied with their treatment. Moreover,
both groups’ mean scores on each subscale of the FACIT-TS-PS, V4 represent a relatively larger
portion of the total possible score on each subscale than that demonstrated on the FACT-Cog.
Mean scores and relative percentages for each group on each selected subscale of the FACIT-TSPS, V4, as well as maximum scores possible for those subscales are reported below, in Graph 3.
Graph 3. Mean Group Scores on Selected Subscales of the Functional Assessment of Chronic
Illness Therapy-Treatment Satisfaction-Patient Satisfaction, Version 4 (FACIT-TS-PS, V4)
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Discussion
Results of this study did not support hypotheses that stated that negative expectations
would lower patients’ self-reports of health-related functioning. Participants scores on the four
subscales of the FACT-Cog, V3, indicated no significant differences between the groups in their
perceptions of cognitive impairments, comments from others, their quality of life, and of their
cognitive abilities.
However, data from this study revealed an unexpected contrast in how patients rated their
cognitive functioning on the FACT-Cog, V3 compared with how they rated their cognitive
functioning on the Perceived Impairments Scale. On the FACT-Cog, V3 patients in both groups
reported few negative cognitive symptoms, while on the Perceived Impairments Scale, patients
in both groups identified with the experience of negative cognitive symptoms both during and
after chemotherapy. Several factors may have contributed to this puzzling finding. First, the
Perceived Impairments Scale expressly refers to the relationship between chemotherapy and
negative cognitive symptoms, while the FACT-Cog, V3 does not. The Perceived Impairments
Scale commences with a definition of chemotherapy-related cognitive impairment that serves to
overtly draw patients’ attention to the relationship between chemotherapy and cognitive
symptoms. Second, immediately after patients’ read that definition they were asked to rate how
strongly they identified with the experience of negative cognitive symptoms during and after
their treatment with chemotherapy. One conclusion that can be drawn is that these features
resulted in greater prime intensity on the Perceived Impairments Scale and this drove higher
scores on this measure compared to scores on the FACT-Cog, V3. Research has shown that
different levels of prime strength can differentially affect self-report (Simmons, C. M., 2010;
Kang, S. K., Galinsky, A. D., Kray, L. J., & Shirako, A., 2015). This is not to say that patients’
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responses on the FACT-Cog, V3 were based on zero prime. Other factors (such as cancer
survivor status) could theoretically contribute to a general or broad sense of threat while
completing the FACT-Cog, V3. However, it seems likely that individuals would experience less
threat activation on a measure that does not overtly attempt to activate it, and more threat
activation on a measure that overtly attempts to activate it.
In addition to ‘prime intensity’, ‘prime familiarity’ may have played a role in higher
scores on the Perceived Impairments Scale. Research in social psychology has demonstrated that
familiarity with a stereotype can serve to reinforce that stereotype (Häfner, M., & Stapel, D. A.,
2009; Wen, F., Zuo, B., 2008). As individuals who had completed chemotherapy, patients were
likely familiar with the CRCI stereotype through their own experience, conversations with
medical providers, other patients, family, and friends (Schagen, S. B., Das, E., & Van Dam, Frits
S. A. M, 2009). The brief, bite-sized and familiar chemotherapy heuristic provided at the start of
the Perceived Impairments Scale could have initiated recognition of that stereotype, thus leading
participants to endorse that heuristic at higher levels than their scores on the FACT-Cog, V3
demonstrated (Häfner, M., & Stapel, D. A., 2009; Wen, F., Zuo, B., 2008). In other words,
patients’ endorsement of the stereotype may have been due to their familiarity with the CRCI
stereotype (which they were reminded of immediately before responding) rather than their actual
experience with negative cognitive symptoms.
The ideas mentioned above, prime intensity and prime familiarity, can be directly applied
to care in real-world treatment settings. These ideas suggest that how others (professionals, other
patients, family, and friends) share information with cancer patients about potential side effects
of treatment or query them about their cognitive functioning could influence their perceptions of
their functioning and consequently their responses on self-report measures. Research that
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examines stereotype propagation supports this idea (Clarkson, J. J., Tormala, Z. L., Rucker, D.
D, 2008; Clarkson, J. J., Tormala, Z. L., Rucker, D. D., & Dugan, R. G., 2013). For example,
Clarkson, Tormala, and Rucker (2008) showed that when group consensus regarding a stereotype
was high, individuals rated that stereotype as more “correct” than when group consensus was
low. In this study, the CRCI stereotype was presented to participants under high consensus
conditions, i.e., as part of an official study taking place at their treatment clinic, authorized by
their own oncologist. These conditions may have suggested to participants that a larger group of
oncologists and researchers likely endorsed the existence of cognitive impairments during and
after chemotherapy, leading them to agree with the stereotype. Therefore, care must be taken in
the design of self-report measures and in routine interactions with cancer patients to avoid
unintentional reinforcement of unhelpful stereotypes.
While stereotype threat research has mainly examined the role of negative expectations
on performance, much is yet to be learned about other possibilities such as whether patients’
perceptions or attitudes about their cognitive functioning could be boosted through positive
priming. The beneficial effects of positive priming were demonstrated in a study by Aisenberg
and colleagues (2015) whereby elderly adults performed better on a cognitive task after receiving
a positive prime that highlighted participants’ cognitive abilities (rather than the association
between older age and cognitive decline. Helping cancer patients to understand the temporary
nature of cognitive symptoms (if they are even experienced) and the degree to which everyday
cognitive failures (normal, minor thinking errors) occur, may serve to boost perceptions of
functioning and ultimately minimize or prevent fears related to cognition after chemotherapy.
For example, forgetting where the car keys were placed likely represents a normal thinking error
and not cognitive decline associated with chemotherapy.
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It is also possible that order effects played a role in participants’ relative endorsement of
the CRCI stereotype versus symptoms on the FACT-Cog. The Perceived Impairments Scale was
not included in the Latin Square technique used to order the measures to avoid interference with
the experimental manipulation. Instead, the Perceived Impairments Scale always occurred in the
final position, therefore patients always completed it last. Patients may have been ambivalent or
fatigued by the time they reached the final measure and therefore may have given mid-range
responses to speed completion or to simplify decision-making. These are not uncommon
occurrences on questionnaires or on Likert-type scales (Huang, J. L., Liu, M., & Bowling, N. A.
2015; Raaijmakers, Q. A. W., van Hoof, A., Hart, H. '., Verbogt, T. F. M. A., & Vollebergh, W.
A. M., 2000).
Further examination of scores on the Perceived Impairments Scale presented another
interesting finding: only the control group reported that their cognitive symptoms decreased over
time. The experimental group reported no such decrease; they reported experiencing the same
level of identification with the CRCI stereotype after treatment as they experienced during
treatment. This result is in opposition to the idea that patients are more likely to report a decrease
in negative cognitive symptoms following treatment than during treatment (Wefel, J. S., Saleeba,
A. K., Buzdar, A. U., Meyers, C. A., 2010; Raffa, R. B., 2011). For those in the experimental
condition, the original experimental manipulation paired with the additional salience of the CRCI
stereotype may have reinforced patients’ perceptions of cognitive impairment. Research has
demonstrated that increasing the number of exposures to a prime through repetition can lead to
greater effects on dependent measures (Smith, E. R., Miller, D. A., Maltner, A. T., Crump, S. A.,
Garcia-Marques, T., & Mackie, D. M., 2006; Wen, F., & Zuo, B., 2008). This finding suggests
that treatment threat may have actually occurred for the experimental group because it follows
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the expected pattern of threat activation followed by endorsement of negative cognitive
symptoms; in this case, negative cognitive symptoms that did not decrease over time as they did
for the control group. Put in the context of treatment, repeated mention of the “chemo-brain”
stereotype, from multiple sources could potentially prime patients to perceive their cognitive
functioning as diminished. This intriguing finding suggests an excellent starting point for further
investigation.
As noted earlier, the primary hypotheses of the study were not supported by the data.
Primary hypotheses postulated that the manipulation (activating treatment threat) would cause
the experimental group to self-report more negative cognitive symptoms (as measured by the
FACT-Cog, V3) and less treatment satisfaction (as measured by the FACIT-TS-PS, V4) than the
control group. These results do not echo results from multiple studies that have shown that
negative stereotypes can negatively influence performance (Croizet & Claire, 1998; Levy, 1996;
Spencer, Steele, & Quinn, 1999; Suhr & Gunstad, 2002; Suhr & Gunstad, 2005; Steele &
Aronson; 1995, & Steele, 1997).
Examination of data from the FACT-Cog, V3 indicate that across all four subscales,
participants in both groups reported strong cognitive functioning. Similarly, data across the
FACIT-TS-PS indicated a high degree of treatment satisfaction. In other words, treatment threat,
if it was produced at all, did not negatively influence self-reports of health-related functioning
for this sample of patients, at this specific clinic. Several methodological issues may have
contributed to these results.
One primary methodological explanation may be related to the process of threat
induction. Other studies examining the phenomenon of stereotype and diagnosis threat have had
different levels of success in activation of a threat in participants (Suhr and Gunstad; 2005;
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Trontel, H. G., Hall, S., Ashendorf, L., O’Connor, M. K., 2013). Trontel and colleagues (2013)
demonstrated that while diagnosis threat was not shown to negatively impact neuropsychological
test performance, diagnosis threat did lower reports of academic self-efficacy in a traumatic brain
injury (TBI) population. Put simply, threat activation can lead to variable effects. As was
previously mentioned, differences in prime intensity (such as a ‘high intensity prime’ vs. a ‘low
intensity prime’) can produce differences in degree of threat activation (Simmons, C. M., 2010;
Kang, S. K., Galinsky, A. D., Kray, L. J., & Shirako, A., 2015). Logic would suggest that the
largest effects would stem from high intensity primes; however, the low intensity level of the
prime in the present study was intentionally selected to prevent emotional distress or feelings of
conflict in survivors regarding their prior treatment with chemotherapy. Thus, statements
intended to activate threat in the experimental group may not have been of sufficient intensity to
produce clear effects on either the FACT-Cog or the FACIT-TS-PS.
A second methodological issue may have been related to the recruitment process. All
participants were recruited during their regularly scheduled maintenance appointments with their
treating oncologist, therefore, all participants knew they were being recruited due to a prior
diagnosis of cancer, and by extension, treatment with chemotherapy. Consequently, there may
not have been a “true” control group. In a sense, all participants may have been primed to some
degree prior to self-report, which may have produced comparable results between the groups on
the FACT- Cog,V3. Likewise, check-up appointments where extremely good news is delivered
(such as stable blood counts and continued remission), may serve to block attempts to induce
threat. Indeed, overt or strong attempts to persuade others from a currently held belief have been
shown to backfire (Tormala, Z. L., & Petty, R. E., 2002). Tormala and Petty (2002) investigated
the effects of resisting persuasion on attitude certainty and found that when the persuasive
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attempt was perceived to be strong, participants’ degree of certainty about their own belief not
only increased, but also limited their vulnerability to persuasive attempts in the future.
Another potential problem was small sample size. In the design of this project, several
factors were attempted to be weighed and balanced carefully. On one hand, larger sample sizes
allow researchers to more easily detect effects if they are present (Hayes, W. L., 1994), however,
a larger patient sample was not feasible in this study given constraints around access to patients
and the limited number of physicians who chose to recruit participants. On the other hand, two
influential and frequently cited papers that examined diagnosis threat in different patient
populations found significant results with small sample sizes (Suhr, J. A., & Gunstad, J., 2002;
Suhr, J. A., & Gunstad, J., 2005). This project was completed with this research in mind and with
the desire to potentially expand the limited information known about the mechanisms that
underlie the “chemo-brain” stereotype.
Lastly, differences in cancer type, cancer stage, and treatment protocols could have
influenced results. These variables were not controlled to maximize the sample size of this
project. It is easy to imagine how these variables might influence patients’ perceptions of not
only their cognitive functioning, but other types of functioning as well. For example, an
individual who experienced an early stage cancer, was treated with less cytotoxic chemotherapy,
and experienced a shorter treatment duration may report fewer cognitive complaints and better
overall functioning than an individual who experienced a more severe diagnosis and more trying
treatment conditions (Argyriou, Assimakopoulos, Iconomou, Giannakopoulou, & Kalofonos,
2011; de Ruiter et al., 2011).
While numerous methodological variables may have contributed to the results of the
study, other “patient-related” variables may also have been at play. Findings in this study may be
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related to a unique quality or set of qualities possessed by this sample of patients that contributed
to their ability to repel threat. All participants were cancer survivors, and as such, they may have
developed strong beliefs and attitudinal characteristics that aided survival following a lifethreatening diagnosis. The emotional and physical challenges of cancer treatment may instill in
patients, certain beliefs and characteristics that buffered them from successful threat induction.
Research on posttraumatic growth after cancer indicates that survivors frequently report
enhanced self-esteem, greater life appreciation and meaning, heightened spitituality, and
heightened benefit-finding following their cancer experience (Andrykowski, M. A., Lykins, E.,
& Floyd, A., 2008). Results from a study by Schagen, Das, & van Dam (2009) supports the idea
that treatment experience may inoculate patients to some extent against threat. Schagen and
colleagues demonstrated that patients with little to no knowledge about CRCI (those who have
had no experience with treatment or exposure to this idea through family and/or friends) may be
more vulnerable to the experience of the ‘chemo-brain’ stereotype than patients with knowledge
of CRCI (those who have had experience with treatment and exposure to this idea through family
and/or friends). Stated in reverse, Schagen and colleagues found that those with more knowledge
were less vulnerable, and this may have been the case for patients in the present study. Other
examples of the effect of attitudes on health outcomes are numerous; for example, optimism, has
been shown to be positively correlated with better treatment outcomes in cardiac patients and
others with chronic illness (Corace, K. M., & Endler, N. S., 2003; Hurt, C. S., Burn, D. J.,
Samuel, M., Wilson, K., & Brown, R., G., 2014).
In addition to patient-related variables, “provider-related” variables may have helped
patients defend against negative expectations and stereotypes. Consistent with patterns of
performance on the FACT-Cog, V3, scores on the FACIT-TS-PS, V4 revealed that participants
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in both groups were highly satisfied with the treatment they received. The FACIT-TS-PS
included items such as, ‘Did your doctor show genuine concern for you?’; ‘Were you
encouraged to participate in decisions about your health care?’; and ‘Did the treatment staff
discuss how your health and treatment may affect you emotionally?’ Participants in both groups
indicated that they received as much physician and treatment staff communication as they
wanted and that the quality of their communication was very high. High quality interactions with
their physicians and other treatment staff may have infused patients with “protection” from
alternative information that may carry a negative valence (such as negative expectations and
stereotypes). Studies have shown that high quality physician-patient and nurse-patient
interactions can increase patients’ confidence in the success of their treatment and create
increased levels of hope for the future (Charlton, C. R., Dearing, K. S., Berry, J. A., & Johnson,
M. J., 2008; Merckaert, I., Libert, Y., & Razavi, D., 2005).
Results from this study illustrate the challenges involved in investigating chemotherapyrelated cognitive impairment. Often, patients’ subjective reports of their cognitive functioning
suggest more impairment than that which is observed by objective measurement. Methodological
issues such as differences in cancer type, treatment type, treatment intensity, measurement
shortcomings, and lack of baseline data have been implicated as causes of disparate findings.
The purpose of this study was to investigate a phenomenon that may influence
performance on subjective measures of functioning. It was proposed that negative expectations
related to the “chemo-brain” stereotype have the power to negatively influence self-perceptions
of cognitive functioning (and perhaps other types of health-related functioning) in cancer
survivors. While the manipulation did not cause the experimental group to report significantly
more negative cognitive symptoms and less treatment satisfaction, other valuable findings
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emerged. Namely, that on one measure patients did identify fairly strongly with the experience of
negative cognitive symptoms during and after treatment, yet on another measure, they reported
very few negative cognitive symptoms. It may be that patients were psychologically buffered
from treatment threat by the attitudes and beliefs that developed through the challenges of coping
with a life-threatening illness, and/or by the strength of their relationships with their care
providers. However, results on the Perceived Impairments Scale suggest that any protective
effect of a psychological buffer diminished under the influence of increasing prime intensity,
prime familiarity, and prime repetition and ultimately led participants in the experimental group
to rate the degree to which they identified with the CRCI stereotype at a moderate level.
Providing patients with a definition and then asking them if their experience fits that definition,
could lead them to identify more strongly with that definition or, in this case, the CRCI
stereotype.
Conclusion
The findings reported here contribute to a growing scientific understanding of the
underlying mechanisms of chemotherapy-related cognitive impairment. Advances in early
diagnosis and treatment have resulted in many more people surviving a diagnosis of cancer
today, than just a short time ago (American Cancer Society, 2014). As the number of survivors
continues to grow, issues related to survivorship will become increasingly important. The
prevalence of negative cognitive symptoms reported by patients (up to 68%), makes this issue an
important topic for consideration by the research community (Ahles & Saykin, 2007; Johnston,
2014; Joly, Rigal, Noal, & Giffard, 2011; Lindner, Phillips, McGabe, Mayes, Wearden, Varese,
& Talmi, 2014; Shilling, Jenkins, & Trapala, 2006). Understanding the factors that influence
perceived cognitive functioning may facilitate the development of intervention programs that
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aim to prevent or moderate the development of unhelpful stereotypes. Eliminating unhelpful
stereotypes as factors that influence patients’ attitudes and beliefs about their functioning, may
ultimately contribute to enhanced quality of life after cancer.
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Appendix A
Demographic Questionnaire
INSTRUCTIONS: Please complete the following screening questionnaire by filling in the
blanks or circling your answers.
Age: _________________

Birthdate: _________________

1. Were there any known difficulties with your birth?

Yes

No

If yes, describe: _____________________________________________________________
2. Do you have a vision problem that requires corrective lens wear (e.g., glasses)?

Yes

No

3. Did you ever have to repeat any grades?

Yes

No

4. Were you ever placed in special education classes?

Yes

No

Education

5. What is the highest level of education you have attained (circle one)?
High School Some college College degree Master’s degree

Doctoral degree

Medical and Health History
6. Have you ever been diagnosed with any neurological condition?

Yes

No

If yes, please list: ___________________________________________________________
7. Are you currently experiencing significant problems with your mental health, such as
problems with anxiety and/or depression, or any other psychiatric condition?
Yes
If yes, please list:

No

___________________________________________________________________________
___________________________________________________________________________
8. Are you currently receiving treatment for your mental health?
If yes, please explain:

Yes

No

______________________________________________________________________________
______________________________________________________________________________
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9. Have you ever felt you should cut down on your drinking/drug use?

Yes

No

10. Have you ever been annoyed by people who criticize your drinking/drug use?

Yes

No

11. Have you ever felt bad or guilty about your drinking or drug use?

Yes

No

12. Have you ever had a drink first thing in the morning to steady your nerves or

Yes

No

13. Do you often drive under the influence of alcohol or drugs?

Yes

No

14. Have you ever been diagnosed with cancer?

Yes

No

to get rid of a hangover?

15. If yes, what type of cancer did you have? _________________________________________
16. If yes, when were you diagnosed with cancer? _____________________________________
17. If yes, how long did your cancer treatment last? ____________________________________
18. If yes, what kind of cancer treatment did you receive?
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
19. If yes, are you finished will all treatments for this cancer?

Yes

No

20. If yes, when did you finish all cancer treatments? ___________________________________
21. Have you ever experienced a concussion or brain injury?

Yes

No

22. Were you knocked unconscious?

Yes

No

If yes, how long were you unconscious? (please circle the letter that corresponds to your
answer)
A. Less than 1 minute
B. 1-30 minutes
C. More than 30 minutes

60

23. Do you remember the events before or after your head injury?

Yes

If no, how long of a time period were you unable to remember?
1. A few seconds
2. Less than 5 minutes
3. Less than 30 minutes
4. 30 to 60 minutes
5. More than 60 minutes

Thank you.
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Appendix B
Instructions NEG
When you finish reading these instructions, sign at the bottom indicating that you have read them and
understand your task. Then, place this signed sheet back into the envelope, seal it, place an X over
the seal and wait for the examiner to return.

You have been invited to participate in this study because you indicated a prior diagnosis of
cancer and treatment with chemotherapy. A number of studies report that some individuals treated
with chemotherapy have reported problems with thinking and memory such as feeling forgetful,
having trouble organizing thoughts, or not being able to think of the right word. Some patients have
reported that these problems have made other aspects of life (i.e., work, school, home life) more
difficult. This study will examine the role that chemotherapy may play in numerous areas of healthrelated functioning.
When the experimenter returns to the room, s/he will ask you to complete a collection of
health-related questionnaires. Please do not leave any questions blank. Some questions may seem
less applicable to your individual situation. Please choose the response that best represents your
experience. Please answer as thoroughly and accurately as possible. Questions about individual
questionnaires will be answered following the testing.

I have read these instructions and will do my best to follow them for the remainder of the experiment.

_______________________________________________________
(Signature)
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Appendix C
Instructions CG

When you finish reading these instructions, sign at the bottom indicating that you have read them and
understand your task. Then, place this signed sheet back into the envelope, seal it, place an X over
the seal and wait for the examiner to return.

When the experimenter returns to the room, s/he will ask you to complete a collection of
health-related questionnaires. Please do not leave any questions blank. Some questions may seem
less applicable to your individual situation. Please choose the response that best represents your
experience. Please answer as thoroughly and accurately as possible. Questions about individual
questionnaires will be answered following the testing.

I have read these instructions and will do my best to follow them for the remainder of the experiment.

_______________________________________________________
(Signature)
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Appendix D
FACT-Cognitive Function (FACT-Cog), Version 3
Below is a list of statements that other people with your condition have said are important. Please
circle or mark one number per line to indicate your response as it applies to the past 7 days.
Never

PERCEIVED COGNITIVE IMPAIRMENTS

About
once a
week

Two to
three
times a
week

Nearly
every
day

Several
times
a day

CogA1

I have had trouble forming thoughts .....................................
0 0

1

2

3

4

CogA3

My thinking has been slow ....................................................
0 0

1

2

3

4

CogC7

I have had trouble concentrating ...........................................
0 0

1

2

3

4

CogM9

I have had trouble finding my way to a familiar
place .......................................................................................
0 0

1

2

3

4

I have had trouble remembering where I put things,
like my keys or my wallet .....................................................
0 0

1

2

3

4

I have had trouble remembering new information,
0 0
like phone numbers or simple instructions ...........................

1

2

3

4

I have had trouble recalling the name of an object
0
while talking to someone ......................................................

1

2

3

4

I have had trouble finding the right word(s) to
0 0
express myself .......................................................................

1

2

3

4

I have used the wrong word when I referred to an
object .....................................................................................
0 0

1

2

3

4

I have had trouble saying what I mean in
conversations with others ......................................................
0 0

1

2

3

4

I have walked into a room and forgotten what I
meant to get or do there .........................................................
0 0

1

2

3

4

I have had to work really hard to pay attention or I
would make a mistake ...........................................................
0 0

1

2

3

4

1

2

3

4

CogM10

CogM12

CogV13

CogV15

CogV16

CogV17b

CogF19

CogF23

CogF24

I have forgotten names of people soon after being
0
introduced .............................................................................. 0
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Please circle or mark one number per line to indicate your response as it applies to
the past 7 days.
Never

About
once a
week

Two to
three
times a
week

Nearly
every
day

Several
times a
day

My reactions in everyday situations have been
slow........................................................................................
0 0

1

2

3

4

I have had to work harder than usual to keep track
0 0
of what I was doing ...............................................................

1

2

3

4

CogC32

My thinking has been slower than usual ...............................
0 0

1

2

3

4

CogC33a

I have had to work harder than usual to express
0 0
myself clearly ........................................................................

1

2

3

4

I have had to use written lists more often than
usual so I would not forget things .........................................
0 0

1

2

3

4

I have trouble keeping track of what I am doing if I
am interrupted ........................................................................
0 0

1

2

3

4

I have trouble shifting back and forth between
different activities that require thinking ................................
0 0

1

2

3

4

CogF25

CogC31

CogC33c

CogMT1

CogMT2

Please circle or mark one number per line to indicate your response as it applies to
the past 7 days.
Never

About
once a
week

Two to
three
times a
week

Nearly
every
day

Several
times a
day

Other people have told me I seemed to have trouble
remembering information ......................................................
0 0

1

2

3

4

Other people have told me I seemed to have trouble
0 0
speaking clearly .....................................................................

1

2

3

4

Other people have told me I seemed to have trouble
0 0
thinking clearly ......................................................................

1

2

3

4

Other people have told me I seemed confused ............... 0

1

2

3

4

COMMENTS FROM OTHERS
CogO1

CogO2

CogO3

CogO4
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Please circle or mark one number per line to indicate your response as it applies to
the past 7 days.
Not
at all

A little
bit

Somewhat

Quite
a bit

Very
much

PERCEIVED COGNITIVE ABILITIES
Cog
PC1

I have been able to concentrate ......................................................
0

1

2

3

4

Cog
PV1

I have been able to bring to mind words that I wanted to
use while talking to someone .........................................................
0

1

2

3

4

Cog
PM1

I have been able to remember things, like where I left
my keys or wallet ...........................................................................
0

1

2

3

4

Cog
PM2

I have been able to remember to do things, like take
medicine or buy something I needed .............................................
0

1

2

3

4

Cog
PF1

I am able to pay attention and keep track of what I am
doing without extra effort ..............................................................
0

1

2

3

4

Cog
PCH
1

My mind is as sharp as it has always been.....................................
0

1

2

3

4

Cog
PCH
2

My memory is as good as it has always been ................................
0

1

2

3

4

Cog
PMT
1

I am able to shift back and forth between two activities
that require thinking .......................................................................
0

1

2

3

4

Cog
PMT
2

I am able to keep track of what I am doing, even if I am
interrupted ......................................................................................
0

1

2

3

4

Please circle or mark one number per line to indicate your response as it applies to
the past 7 days.

Not
at all

CogQ3
5
CogQ3
7

CogQ3
8

CogQ4
1

A little
bit

Somewhat

Quite
a bit

Very
much

2

3

4

These problems have interfered with my ability to
work .......................................................................................
0
0 1

2

3

4

These problems have interfered with my ability to
do things I enjoy ....................................................................
0
0 1

2

3

4

2

3

4

IMPACT ON QUALITY OF LIFE
I have been upset about these problems ................................
0
0 1

These problems have interfered with the quality
0
1
of my life ...............................................................................
0
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Appendix E
FACIT-Treatment Satisfaction-Patient Satisfaction (FACIT-TS-PS), Version 4
These questions are about the quality of the health care services you are currently receiving. All of
your responses will be kept confidential. Please mark one answer for each of the following
questions. Pleasecircle or mark one number per line to indicate your response as it applies to
the past 7 days.
No, not at
all

Yes, but
not as
much as I
wanted

Yes,
almost as
much as I
wanted

Yes, and
as much
as I
wanted

Did your doctor(s) give explanations that you could
understand? ...................................................................

0

1

2

3

Did your doctor(s) explain the possible benefits of
your treatment? .............................................................

0

1

2

3

Did your doctor(s) explain the possible side effects
or risks of your treatment? ............................................

0

1

2

3

TS12

Did you have an opportunity to ask questions? ............

0

1

2

3

TS13

Did you get to say the things that were important to
you? ............................................................................

0

1

2

3

Did your doctor(s) seem to understand what was
important to you? ........................................................

0

1

2

3

TS15

Did your doctor(s) show genuine concern for you? ...

0

1

2

3

TS16

Did your doctor(s) seem to understand your needs? ..

0

1

2

3

TS18

Were you able to talk to your doctor(s) when you
needed to? ...................................................................

0

1

2

3

Were you encouraged to participate in decisions
about your health care? ..................................................

0

1

2

3

Did you have enough time to make decisions about
your health care?............................................................

0

1

2

3

Did your doctor(s) seem to respect your opinions? .......

0

1

2

3

Physician Communication

TS9

TS10

TS11

TS14

TS27

TS28

TS30
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No, not
at all

Yes, but
not as
much as I
wanted

Yes,
almost as
much as I
wanted

Yes,
and as
much as I
wanted

Did the treatment staff discuss how your health and
treatment may affect your normal work (including
housework)? .................................................................... 0

1

2

3

Did the treatment staff discuss how your health and
treatment may affect your normal daily activities? ......... 0

1

2

3

Did the treatment staff discuss how your health and
treatment may affect your personal relationships? .......... 0

1

2

3

Did the treatment staff discuss how your health and
treatment may affect you emotionally? ........................... 0

1

2

3

No, not
at all

Yes, but
not as
much as I
wanted

Yes,
almost as
much as I
wanted

Yes,
and as
much as I
wanted

Did you feel your doctor(s) had experience treating
your illness? ...................................................................

0

1

2

3

Did you feel your doctor(s) knew about the latest
medical developments for your illness? ........................

0

1

2

3

Was the treatment staff thorough in examining and
treating you? ..................................................................

0

1

2

3

No, not at
all

Yes, but
not as
much as I
wanted

Yes,
almost as
much as I
wanted

Yes, and
as much
as I
wanted

Treatment Staff Communication

TS19

TS20

TS21

TS22

Technical Competence
TS23

TS24

TS25

Nurse Communication

Did your nurse(s) give explanations that you could
understand? ....................................................................

0

1

2

3

TS32

Did your nurse(s) show genuine concern for you? ........

0

1

2

3

TS33

Did your nurse(s) seem to understand your needs? .......

0

1

2

3

TS31
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No, not
at all

Yes, but
not as
much as
I wanted

Yes,
almost as
much as
I wanted

Yes, and as
much as I
wanted

Did you feel that the treatment staff answered your
questions honestly? .....................................................

0

1

2

3

TS35

Did the treatment staff respect your privacy?.............

0

1

2

3

TS36

Did you have confidence in your doctor(s)? ..............

0

1

2

3

TS37

Did you trust your doctor(s)' suggestions for
treatment? ...................................................................

0

1

2

3

No

Maybe

Yes

Would you recommend this clinic or office to
others?......................................................................

0

1

2

Would you choose this clinic or office again? ........

0

1

2

Confidence and Trust
TS34

Overall

TS38

TS39

TS40

How do you rate the care you received? ................

Thank you! Do you have any comments?
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Poor

Fair

Good

Very
Good

Excellent

0

1

2

3

4

Appendix F
Perceived Impairments Scale
Current research on cancer recovery describes chemotherapy-related cognitive impairment as the
experience of having problems with attention, concentration, and memory during and following
treatment with chemotherapy. Due to these problems, some individuals treated with
chemotherapy have reported difficulty returning to the activities of daily living following
treatment, like following medication regimens, managing medical appointments, returning to
work or school, managing a household, and other activities that require multitasking skills.
How accurately does this description represent your experience during chemotherapy (circle
one)?
1

2

3

4

5

6

Not accurately
at all

7
Perfectly
accurately

How accurately does this description represent your experience after chemotherapy (circle
one)?
1

2

3

4

5

Not accurately
at all

6

7
Perfectly
accurately

Comments:
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Appendix G
Debriefing Statement
Thank you for participating in this study. Throughout the course of this experiment, you may
have had questions regarding the nature or purpose of this study. If you still have these
questions, the experimenter will be glad to answer them for you at this time.
The purpose of this study was to investigate the influence of negative expectations on symptom
reporting. Specifically, this study was interested in examining whether or not drawing your
attention to your previous diagnosis of cancer and your treatment with chemotherapy influenced
your performance on subjective measures of functioning. Your answers to these questions, as
well as your performance on the testing measures, will be kept completely confidential.
Although a slight amount of discomfort is normal, if you experienced a significant amount of
discomfort during the course of the experiment, please address your concerns to the experimenter
at the present time. If you feel uncomfortable doing so, you may contact the faculty supervisor
of the project, Dr. Stuart Hall, at 243-5667. If you experience significant discomfort and would
like to explore counseling or mental health services, students can be seen at the Clinical
Psychology Center, at 243-2367 or at Counseling and Psychological Services through the Curry
Health Center, at 243-4711.
IMPORTANT:
We request that you not discuss the details of this experiment with anyone who may be a future
participant in the study. Thank you for your cooperation.
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